文献速递鼻科

评估一种为慢性鼻窦炎提供长期局部类固醇治疗的新型药物递送系统安全性的1期临床研究

Phase 1 clinical study to assess the safety of a novel drug delivery system providing long-term topical steroid therapy for chronic rhinosinusitis.
PubMed 文献 · Int Forum Allergy Rhinol · 2019-01-15

这项前瞻性、多中心、开放标签研究在20例适合内镜鼻窦手术的慢性鼻窦炎患者中,于双侧中鼻道置入新型可生物降解糠酸莫米松递送系统LYR-210(设计为24周持续局部类固醇治疗)。24周内无产品相关严重不良事件,86%的储库仍保留在中鼻道,SNOT-22评分自第1周起显著降低并持续至第24周(p < 0.01)。结论认为LYR-210在未接受过内镜鼻窦手术的慢性鼻窦炎患者中安全且耐受良好,并带来持续的症状改善。

要点

  • LYR-210在20例慢性鼻窦炎患者中双侧置入成功,24周内无产品相关严重不良事件。
  • 第24周时86%的LYR-210储库仍保留在中鼻道。
  • SNOT-22评分自第1周起显著降低并持续至第24周(p < 0.01)。

核心结论

  • LYR-210在未接受过内镜鼻窦手术的慢性鼻窦炎患者中安全且耐受良好,并带来持续的症状改善。

研究设计与样本

  • 前瞻性、多中心、开放标签研究,纳入20例被判定为内镜鼻窦手术候选者的慢性鼻窦炎受试者。

主要发现

  • LYR-210在20例受试者(12例无鼻息肉、8例有鼻息肉)中于诊室环境下双侧置入成功。
  • 截至24周无产品相关严重不良事件,此时86%的LYR-210储库仍保留在中鼻道。
  • 血清皮质醇、眼内压和血浆药物浓度在所有检测时间点均支持全身安全性。
  • 受试者SNOT-22评分自第1周起显著降低,并持续至第24周(p < 0.01)。
  • 第24周时SNOT-22的鼻部、鼻外鼻部、耳面部、心理和睡眠功能障碍子领域均达到显著症状改善(p < 0.05)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic rhinosinusitis (CRS) patients who fail medical management have few treatment options other than endoscopic sinus surgery (ESS). A novel biodegradable mometasone furoate drug delivery system (LYR-210) providing continuous topical steroid therapy to sinonasal mucosa over 24 weeks was developed to treat unoperated CRS patients who have failed medical management prior to ESS. LYR-210 was designed to slowly expand in the middle meatus, ensuring efficient drug delivery as mucosal swelling reduces. METHODS: A prospective, multicenter, open-label study was conducted in 20 CRS subjects who were determined to be candidates for ESS. Under endoscopic guidance and topical anesthesia, LYR-210 was placed in both middle meatuses. The primary endpoint was product-related serious adverse events (SAEs) at 4 weeks. Additional assessments included plasma drug concentration, morning serum cortisol levels, intraocular pressures (IOPs), and Sino-Nasal Outcome Test (SNOT-22) scores. RESULTS: LYR-210 was successfully placed bilaterally in 20 subjects (12 without nasal polyps and 8 with polyps) in an office setting. There were no product-related SAEs through 24 weeks, at which point 86% of LYR-210 depots were still retained in the middle meatus. Serum cortisol, IOP, and plasma drug concentrations supported systemic safety at all time points tested. Subjects experienced significant reductions in their SNOT-22 scores as early as week 1, and this reduction persisted through week 24 (p < 0.01). Significant symptom improvement was achieved in the SNOT-22 rhinologic, extranasal rhinologic, ear-facial, psychological, and sleep dysfunction subdomains at 24 weeks (p < 0.05). CONCLUSION: LYR-210 is safe and well-tolerated in ESS-naive CRS patients and leads to sustained symptom improvement in patients.

来源:Int Forum Allergy Rhinol,查看原文。版权归原作者所有。

引用

  1. Douglas RG, Psaltis AJ, Rimmer J, et al. Phase 1 clinical study to assess the safety of a novel drug delivery system providing long-term topical steroid therapy for chronic rhinosinusitis. Int Forum Allergy Rhinol. 2019. PMID: 30645028. doi:10.1002/alr.22288

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。